

Basic information	
2020/2786(DEA) DEA - Delegated acts procedure	Procedure completed - delegated act enters into force
Inclusion of the new psychoactive substance N,N-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1-ethanamine (isotonitazene) in the definition of 'drug' (amend. the Annex to Council Framework Decision 2004/757/JHA) Supplementing 2013/0304(COD) Subject 4.20.03 Drug addiction, alcoholism, smoking 7.30.30.04 Action to combat drugs and drug-trafficking	

Key players			
European Parliament	Committee responsible	Rapporteur	Appointed
	LIBE Civil Liberties, Justice and Home Affairs		

Key events			
Date	Event	Reference	Summary
02/09/2020	Non-legislative basic document published	C(2020)05897	
09/09/2020	Initial period for examining delegated act 2 month(s)		
16/09/2020	Committee referral announced in Parliament		
17/11/2020	Delegated act not objected by Parliament		

Technical information	
Procedure reference	2020/2786(DEA)
Procedure type	DEA - Delegated acts procedure
Procedure subtype	Examination of delegated act
Amendments and repeals	Supplementing 2013/0304(COD)
Stage reached in procedure	Procedure completed - delegated act enters into force
Committee dossier	LIBE/9/04106

Documentation gateway			
European Commission			
Document type	Reference	Date	Summary

Non-legislative basic document	C(2020)05897	02/09/2020	